Treatment for OUD is currently dominated by opioid agonist therapies that are highly regulated due to their liability for abuse.

For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 ...

The shortage of semaglutide injections (Ozempic, Wegovy) is over, the FDA announced on Friday. The agency, along with maker ...

Pharma major, Granules India on Saturday said that its board has approved to acquire 100% stake in Senn Chemicals AG, a Swizterland based company, for a total consideration of Rs 192.5 crore. Krishna ...

Senn develops and manufactures, peptides and peptides-based applications for its global customers, providing contract research, development, and manufacturing services.

Granules India said that its board has approved to acquire 100% stake in Senn Chemicals AG, a Swizterland based company, for a total consideration of Rs 192.5 crore (CHF 20 million).

The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper ...

British patients with obesity undergoing hip and knee replacements had less of a need for subsequent revision when, after surgery, they lost weight by using medications such as GLP-1 receptor agonists ...

Hyderabad-based Granules India has signed an agreement to acquire Senn Chemicals AG, a Swiss-based CDMO specializing in peptides, for CHF 20 million (approx. Rs 192 crore). Senn develops and ...

Granules India Limited announces acquisition agreement with Senn Chemicals AG, a Swiss-based CDMO specializing in peptides.

Excluding people with type 2 diabetes from the trial might have resulted in a missed opportunity to establish whether people with both Parkinson's disease and type 2 diabetes could benefit from GLP-1 ...

GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.